Acute Respiratory Distress Syndrome (ARDS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major acute respiratory distress syndrome (ARDS) markets are expected to exhibit a CAGR of 10.1% during 2024-2034.
The acute respiratory distress syndrome (ARDS) market has been comprehensively analyzed in IMARC's new report titled "Acute Respiratory Distress Syndrome (ARDS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute respiratory distress syndrome (ARDS) refers to a severe and life-threatening lung condition characterized by the rapid onset of breathing difficulties and impaired oxygenation of the blood. This ailment typically occurs as a result of an underlying injury or illness, such as pneumonia, sepsis, or trauma, which triggers an inflammatory response in the lungs. Common symptoms of ARDS include severe shortness of breath, rapid and shallow breathing, low oxygen levels in the blood, and the sensation of chest tightness. Individuals suffering from the disorder may also experience confusion and fatigue due to decreased oxygen supply to vital organs. The diagnosis of ARDS involves a combination of clinical evaluation, chest X-rays, and blood gas analysis. A critical criterion for diagnosis is the presence of bilateral opacities on a chest X-ray that cannot be explained by various other conditions. Additionally, arterial blood gas tests reveal low oxygen levels and impaired lung function in patients.
The increasing incidences of several associated risk factors, such as pneumonia, severe infection, inhalation of harmful substances, direct lung injury, chest trauma, drug overdose, pancreatitis, etc., are primarily driving the acute respiratory distress syndrome (ARDS) market. In addition to this, the inflating utilization of effective treatments, including mechanical ventilation, positive end-expiratory pressure (PEEP), and prone positioning, to manage the condition and alleviate breathing difficulty is also creating a positive outlook for the market. Moreover, the widespread adoption of pharmacological interventions like corticosteroids and neuromuscular blockers, as well as the exploration of potential drug candidates targeting inflammation and lung injury pathways, is further bolstering the market growth. Apart from this, the rising usage of precision medicine approaches, where genetic and molecular factors are considered to tailor treatment strategies, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal membrane oxygenation (ECMO) techniques, which provide vital oxygenation and circulation support to the patient's body, thereby enhancing outcomes, is also augmenting the market growth. Furthermore, the ongoing research into innovative therapies, including stem cell-based regenerative approaches and the development of artificial lungs, is expected to drive the acute respiratory distress syndrome (ARDS) market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acute respiratory distress syndrome (ARDS) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute respiratory distress syndrome (ARDS) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute respiratory distress syndrome (ARDS) market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acute respiratory distress syndrome (ARDS) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acute respiratory distress syndrome (ARDS) market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acute respiratory distress syndrome (ARDS) marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acute respiratory distress syndrome (ARDS) market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acute respiratory distress syndrome (ARDS) market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acute respiratory distress syndrome (ARDS) market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acute respiratory distress syndrome (ARDS) across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute respiratory distress syndrome (ARDS) by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute respiratory distress syndrome (ARDS) by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acute respiratory distress syndrome (ARDS) across the seven major markets?
What is the size of the acute respiratory distress syndrome (ARDS) patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acute respiratory distress syndrome (ARDS)?
What will be the growth rate of patients across the seven major markets?
Acute Respiratory Distress Syndrome (ARDS): Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acute respiratory distress syndrome (ARDS) drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute respiratory distress syndrome (ARDS) market?
What are the key regulatory events related to the acute respiratory distress syndrome (ARDS) market?
What is the structure of clinical trial landscape by status related to the acute respiratory distress syndrome (ARDS) market?
What is the structure of clinical trial landscape by phase related to the acute respiratory distress syndrome (ARDS) market?
What is the structure of clinical trial landscape by route of administration related to the acute respiratory distress syndrome (ARDS) market?
The acute respiratory distress syndrome (ARDS) market has been comprehensively analyzed in IMARC's new report titled "Acute Respiratory Distress Syndrome (ARDS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute respiratory distress syndrome (ARDS) refers to a severe and life-threatening lung condition characterized by the rapid onset of breathing difficulties and impaired oxygenation of the blood. This ailment typically occurs as a result of an underlying injury or illness, such as pneumonia, sepsis, or trauma, which triggers an inflammatory response in the lungs. Common symptoms of ARDS include severe shortness of breath, rapid and shallow breathing, low oxygen levels in the blood, and the sensation of chest tightness. Individuals suffering from the disorder may also experience confusion and fatigue due to decreased oxygen supply to vital organs. The diagnosis of ARDS involves a combination of clinical evaluation, chest X-rays, and blood gas analysis. A critical criterion for diagnosis is the presence of bilateral opacities on a chest X-ray that cannot be explained by various other conditions. Additionally, arterial blood gas tests reveal low oxygen levels and impaired lung function in patients.
The increasing incidences of several associated risk factors, such as pneumonia, severe infection, inhalation of harmful substances, direct lung injury, chest trauma, drug overdose, pancreatitis, etc., are primarily driving the acute respiratory distress syndrome (ARDS) market. In addition to this, the inflating utilization of effective treatments, including mechanical ventilation, positive end-expiratory pressure (PEEP), and prone positioning, to manage the condition and alleviate breathing difficulty is also creating a positive outlook for the market. Moreover, the widespread adoption of pharmacological interventions like corticosteroids and neuromuscular blockers, as well as the exploration of potential drug candidates targeting inflammation and lung injury pathways, is further bolstering the market growth. Apart from this, the rising usage of precision medicine approaches, where genetic and molecular factors are considered to tailor treatment strategies, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal membrane oxygenation (ECMO) techniques, which provide vital oxygenation and circulation support to the patient's body, thereby enhancing outcomes, is also augmenting the market growth. Furthermore, the ongoing research into innovative therapies, including stem cell-based regenerative approaches and the development of artificial lungs, is expected to drive the acute respiratory distress syndrome (ARDS) market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acute respiratory distress syndrome (ARDS) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute respiratory distress syndrome (ARDS) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute respiratory distress syndrome (ARDS) market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acute respiratory distress syndrome (ARDS) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acute respiratory distress syndrome (ARDS) market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acute respiratory distress syndrome (ARDS) marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acute respiratory distress syndrome (ARDS) market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acute respiratory distress syndrome (ARDS) market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acute respiratory distress syndrome (ARDS) market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acute respiratory distress syndrome (ARDS) across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute respiratory distress syndrome (ARDS) by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute respiratory distress syndrome (ARDS) by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acute respiratory distress syndrome (ARDS) across the seven major markets?
What is the size of the acute respiratory distress syndrome (ARDS) patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acute respiratory distress syndrome (ARDS)?
What will be the growth rate of patients across the seven major markets?
Acute Respiratory Distress Syndrome (ARDS): Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acute respiratory distress syndrome (ARDS) drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute respiratory distress syndrome (ARDS) market?
What are the key regulatory events related to the acute respiratory distress syndrome (ARDS) market?
What is the structure of clinical trial landscape by status related to the acute respiratory distress syndrome (ARDS) market?
What is the structure of clinical trial landscape by phase related to the acute respiratory distress syndrome (ARDS) market?
What is the structure of clinical trial landscape by route of administration related to the acute respiratory distress syndrome (ARDS) market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - UNMET NEEDS
10 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - KEY ENDPOINTS OF TREATMENT
11 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - MARKETED PRODUCTS
11.1 List of Acute Respiratory Distress Syndrome (ARDS) Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - PIPELINE DRUGS
12.1 List of Acute Respiratory Distress Syndrome (ARDS) Pipeline Drugs Across the Top 7 Markets
12.1.1 MultiStem - Athersys
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 GEn-1124 - GEn1E Lifesciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Reparixin - Dompй Farmaceutici
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ExoFlo - Direct Biologics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
16 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - UNMET NEEDS
10 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - KEY ENDPOINTS OF TREATMENT
11 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - MARKETED PRODUCTS
11.1 List of Acute Respiratory Distress Syndrome (ARDS) Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - PIPELINE DRUGS
12.1 List of Acute Respiratory Distress Syndrome (ARDS) Pipeline Drugs Across the Top 7 Markets
12.1.1 MultiStem - Athersys
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 GEn-1124 - GEn1E Lifesciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Reparixin - Dompй Farmaceutici
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ExoFlo - Direct Biologics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Respiratory Distress Syndrome (ARDS) - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Respiratory Distress Syndrome (ARDS) - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Respiratory Distress Syndrome (ARDS) - Access and Reimbursement Overview
16 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
